Q3 2025 Curis Inc Earnings Call Transcript

Nov 6, 2025 / 09:30 PM GMT

Release Date Price: €1.21 (-1.63%)

Transcript 10-Q8-K

Key Points

Positve

Curis Inc (CRIS) is making steady progress in their Take Aim Lymphoma study, which could support accelerated submissions in the US and Europe.
The company is exploring the potential of emusertib to change the treatment paradigm for CLL patients, aiming for deeper responses and improved quality of life.
Initial data from the AML triplet study shows promising MRD conversion rates, with no disease progression observed among patients.
Curis Inc (CRIS) reported a reduced net loss for Q3 2025 compared to the same period in 2024, indicating improved financial management.
The company has sufficient cash and cash equivalents to fund operations into 2026, providing a stable financial outlook.

Negative

Curis Inc (CRIS) continues to operate at a net loss, with $7.7 million reported for Q3 2025.
Research and development expenses, although reduced, still represent a significant cost, impacting overall financial performance.
The company anticipates the need to raise additional capital before the end of the year, indicating potential financial constraints.
There are dose-limiting toxicities observed in the AML triplet study, which could impact the study's progression and outcomes.
The success of ongoing studies is contingent on regulatory approvals and successful patient enrollment, which carry inherent risks and uncertainties.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CRIS.OQ - Curis Inc
Q3 2025 Curis Inc Earnings Call
Nov 06, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon ladies and gentlemen, and welcome to the Curious 3rd quarter 2025 business update conference call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press 0 for the operator. This call is being recorded on Thursday, November 6, 2025. I would now like to turn the conference over to Diana Duval, Chief Financial Officer. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you and welcome to the Curis 3rd quarter 2025 business

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.